Introduction
============

Breast cancer (BC) is one of the most common malignancies in women, with \~30% of all BC cases possessing genetic origins. Hereditary factors involve mutations of numerous genes, including the genes for breast cancer type 1 susceptibility protein/breast cancer type 2 susceptibility protein (BRCA1/2), cellular tumor antigen p53 (p53) and phosphatase and tensin homolog, and represent a familial aggregation, although a small proportion of hereditary BCs have no familial origin ([@b1-ol-0-0-10046]). The most frequent mutations in hereditary BCs involve the genes coding for BRCA1 and BRCA2 ([@b1-ol-0-0-10046]), which increase the risk of familial breast cancer (FBC) by \~16% ([@b2-ol-0-0-10046]). Patients with FBC can pass these mutations to their children, who have a significantly increased risk of developing breast or ovarian cancer ([@b3-ol-0-0-10046]). However, the role of BRCA1/2 expression in sporadic breast cancer (SBC) remains unclear.

Fanconi anemia (FA) is a rare autosomal recessive disease that involves various types of cytopenias, congenital malformations and neoplastic diseases ([@b4-ol-0-0-10046]). In the FA pathway, which is mainly activated through the S phase of the cell cycle, DNA damage repair is regulated by interactions between a large number of proteins, including FA group A protein (FANCA), FANCB, FANCC, FANCD1 (also known as BRCA2), Fanconi anemia group D2 protein (FANCD2), FANCE, FANCF, FANCG, FANCI, BRCA1 interacting protein C-terminal helicase 1 (FANCJ), E3 ubiquitin-protein ligase FANCL (FANCL), FANCM, partner and localizer of BRCA2 (FANCN), DNA repair protein RAD51 homolog 3 (FANCO), SLX4 structure-specific endonuclease subunit (FANCP), DNA repair endonuclease XPF (FANCQ), DNA repair protein RAD51 homolog 1 (FANCR), FANCS (also known as BRCA1) and Ubiquitin-conjugating enzyme E2 T (FANCT) ([@b5-ol-0-0-10046]). When exogenous DNA damage induces replication blockage, the aborted replication fork activates nuclear FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL and FANCM to form the upstream E3 ubiquitin ligase complex through phosphorylation modification. This complex is crucial for the downstream mono-ubiquitination of FANCD2 at Lys561, which represents the central step in FA pathway activation ([@b6-ol-0-0-10046],[@b7-ol-0-0-10046]). The FANCD2 gene encodes a 1,451-amino acid protein and comprises 44 exons that are located in 3p25.3, with a mutation probability of \~3% ([@b8-ol-0-0-10046],[@b9-ol-0-0-10046]). Ubiquitinated FANCD2 is considered as the long-form of FANCD2 (FANCD2-L; 162 kDa) compared with its non-ubiquitinated version FANCD2-S, which is 155 kDa. FANCD2-S conversion into FANCD2-L can be activated by DNA cross-linking agents, ultraviolet radiation and ionizing radiation in a time- and dose-dependent manner ([@b10-ol-0-0-10046]). The final step of ubiquitination involves the aggregation of ubiquitinated FANCD2 to DNA double-strand breaks, where it interacts with BRCA1/FANCS, BRCA2/FANCD1, FANCN, FANCJ, FANCP and other nuclear proteins to repair intra-DNA cross-link damage and maintain replication fork stability ([@b9-ol-0-0-10046]--[@b13-ol-0-0-10046]). FANCD2 therefore serves a central role in the FA pathway, and its ubiquitination is a crucial process in DNA damage repair.

BRCA1 is present in and co-colocalizes with the downstream FA pathway proteins ([@b14-ol-0-0-10046]). Domchek *et al* ([@b15-ol-0-0-10046]) reported that BRCA1 serves a central role in the FA pathway and that the BRCA1 gene may be involved in FA development. In this context, these findings suggest that BRCA1 mutation can increase the risk of FBC, although its role in SBC remains unclear. Further studies are therefore required to determine the associations and prognostic value of BRCA1 and FANCD2 in FBC and SBC. The present study used immunohistochemistry and western blotting to detect BRCA1 and FANCD2 expression in FBC and SBC tissues samples, and aimed to evaluate their association with the clinical characteristics and prognosis of the patients.

Materials and methods
=====================

### Patient selection and data collection

The present study was approved by the Ethics Committee of The First Affiliated Hospital of China Medical University (Shenyang, Liaoning, China). All enrolled patients provide written informed consent prior to the study.

Specimens from 335 patients with BC who underwent breast surgery between January 2004 and January 2009 at The First Affiliated Hospital of China Medical University were randomly selected. All patients had undergone modified radical mastectomy with no trace of distant metastasis at the diagnosis and received no neoadjuvant therapy prior to the study. The 335 BC cases comprised 141 FBC and 147 SBC cases, and 47 control cases of benign breast tumors. The FBC group included patients who had a first-degree relative with a history of BC, whereas the SBC group included patients with no familial history of BC. Clinical characteristics were retrospectively collected and included age, pathological type, histological grade, tumor size, lymph node infiltration, Tumor-Node-Metastasis (TNM) stage ([@b16-ol-0-0-10046]), estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status, and Ki-67 index. All patients were followed up clinically until January 2016, and the disease-free survival (DFS) time was calculated from the time of surgery to the first occurrence of relapse, progression or mortality from any cause, or the last follow-up.

### Immunohistochemistry

A standard indirect immunoperoxidase protocol was used for the immunohistochemical analysis ([@b17-ol-0-0-10046]). Briefly, at room temperature, the paraffin-embedded tumor tissue sample were placed in 4% paraformaldehyde for 3 h and then 4-µm thick sections were deparaffinized, rehydrated and blocked using 3% hydrogen peroxide for 15 min. Samples were then incubated at 120°C for 1 min to expose antigens, and allowed to cool to room temperature. Tissues were blocked with 1% bovine serum albumin (Reagent A, KIT-9710 UltraSensitive™ SP (Mouse/Rabbit) IHC Kit, MXB Biotechnology) at room temperature to avoid non-specific binding, and labeled with the mouse anti-human primary antibodies against BRCA1 (cat. no. sc-56030; 1:200) and FANCD2 (cat. no. sc-20022; 1:150) (both Santa Cruz Biotechnology, Inc., Dallas, TX, USA). Sections were incubated with primary antibodies overnight at 4°C in a humidified chamber. Sections were then further incubated with the UltraSensitive™ SP (Mouse/Rabbit) IHC kit (KIT-9710; Fuzhou Maixin Biotech Co., Ltd., Fuzhou, China) at room temperature for 10 min and visualized by staining with 3,30-diaminobenzidine tetrahydrochloride (Fuzhou Maixin Biotech Co., Ltd) at room temperature for 10 min. Sections were counterstained with hematoxylin at room temperature for 10 min, dehydrated in 75, 85, 95 and 100% absolute ethanol for 2 min and covered with coverslips. Positive controls were selected from previously diagnosed sections at the Department of Pathology, The First Affiliated Hospital of China Medical University. Sections that were not stained with primary antibodies represented negative controls. Two pathologists independently scored each section by analyzing 10 fields under an optical microscope (magnification, ×200) that contained \>200 cells. Nuclear and cytoplasmic staining for BRCA1 was scored as either negative, or mildly, moderately or strongly positive for \<5, 5--25, 25--50 or \>50% stained cells, respectively ([@b18-ol-0-0-10046]). FANCD2 nuclear staining was scored as either negative, or mildy, moderately or strongly positive for \<5, 5--25, 25--50 or \>50% stained cells, respectively ([@b19-ol-0-0-10046]). Patients with samples that were mildy, moderately or strongly stained were assigned to the positive expression group.

### Western blotting

Western blotting was used to detect FANCD2 ubiquitination level in 56 randomly selected frozen SBC specimens. Tumor tissues were frozen in liquid nitrogen and homogenized using a membrane and cytosol protein extraction kit (cat. no. P0033; Beyotime Institute of Biotechnology, Haimen, China) to extract proteins. Tissues were crushed and washed with PBS and lysed in 100 µl lysis buffer (catalog no. 78833; Thermo Fisher Scientific, Inc.). Cell lysates were centrifuged at room temperature, at 13,500 × g for 5 min. Protein concentration was determined by the BCA method (catalog no. P0012S; Beyotime Institute of Biotechnology). Equal amounts of proteins (50 µg) were separated by SDS-polyacrylamide gel electrophoresis, and transferred onto a nitrocellulose membrane (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Membranes were blocked with 5% fat-free milk diluted with TBST (10 mM Tris-HCl, Ph 7.4, 150 mM NaCl, 0.1% Tween-20) at room temperature for 1 h and incubated for 1 h with the rabbit anti-human primary antibodies against FANCD2 (cat. no. sc-28194; 1:1,000) and β-actin (cat. no. sc-47778; 1:3,000) (both Santa Cruz Biotechnology). Membranes were then incubated with a horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (1:5,000; cat. no. A0545; Sigma-Aldrich; Merck KGaG) at room temperature for 1 h. Membranes were washed three times for 5 min, and visualized using a Pierce enhanced chemiluminescence substrate (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Gel-pro software (version 6.0; Media Cybernetics, Inc., Rockville, MD, USA) was used to analyze the net absorbance values of protein bands and internal reference bands. FA proteins were visualized as two bands, of which the upper (L) and lower (S) bands represented the ubiquitinated and un-ubiquitinated FANCD2, respectively. The L/S ratio indicated the FANCD2 ubiquitination degree ([@b20-ol-0-0-10046],[@b21-ol-0-0-10046]).

### Statistical analysis

All statistical analysis was performed using SPSS 24.0 (IBM Corp., Armonk, NY, USA). P\<0.05 was considered to indicate a statistically significant difference. Patient clinical characteristics were compared using the χ^2^ test. Survival analyses were assessed using the Kaplan-Meier (KM) method and the two-tailed log-rank test. Univariable and multivariable analyses were performed using a Cox proportional hazard model to evaluate the effects of BRCA1 and FANCD2 expression on DFS. Results were reported as hazard ratios (HRs) and 95% confidence intervals (CI).

### Expression of BRCA1 and FANCD2 based on The Cancer Genome Atlas (TCGA) dataset

Further analyses of BRCA1 and FANCD2 gene expression in BC tissues were conducted based on The Cancer Genome Atlas (TCGA) dataset (<https://cancergenome.nih.gov/>) ([@b22-ol-0-0-10046]). In addition, the Gene Expression Profiling Interactive Analysis (GEPIA) dataset (<http://gepia.cancer-pku.cn/>) was used to compare BRCA1 and FANCD2 gene expression between BC tissues and their adjacent non-cancerous tissues ([@b23-ol-0-0-10046]). GEPIA data were analyzed using an unpaired Student\'s t-test. To verify the associations between BRCA1 and FANCD2 gene expression and clinical characteristics, data obtained from 1,080 patients with BC in the TCGA dataset were analyzed using the χ^2^ test.

Results
=======

### Patient clinical characteristics

The 47 women included in the benign tumor group presented with various types of tumors, including fibroadenoma, cystic hyperplasia, intraductal papilloma and sclerosing adenosis (15, 24, 7 and 1 cases, respectively), and had a median age at diagnosis of 46 years (range, 18--71 years). The remaining 288 women with primary malignant breast cancer ([Table I](#tI-ol-0-0-10046){ref-type="table"}) were divided into the FBC (n=141) and SBC (n=147) groups. Patients in the FBC and SBC groups had a median age at diagnosis of 52 years (range, 31--76 years) and 50 years (range, 25--79 years), respectively. The malignant tumors included intraductal carcinoma, invasive ductal carcinoma, invasive lobular carcinoma and other rare types (39, 172, 47 and 30 cases, respectively). The histological types were predominantly of type I (FBC, 30.5%; SBC, 21.1%) and type II (FBC, 47.5%; SBC, 53.1%), and large proportions of the tumors were considered as stage T1 (46.9%), T2 (43.1%) or involving lymphatic invasion (41%). According to the 2017 American Joint Committee on Cancer criteria ([@b24-ol-0-0-10046]), the majority of patients had stage I (FBC, 43.3%; SBC, 37.4%) or stage II (FBC, 36.2%; SBC, 38.1%) disease. The follow-up ended in January 2016, with a median follow-up time of 74.4 months (range, 4--155 months). The median DFS time was 91.8 months, with 1-, 3- and 5-year DFS rates of 97.9, 91.7 and 83.3%, respectively. A total of 24 (8.33%) local recurrences and 29 (10.08%) distant metastases occurred within 5 years.

### Immunohistochemical staining for BRCA1 and FANCD2

The typical staining for BRCA1 was nuclear and cytoplasmic in the benign and malignant tissues ([Fig. 1](#f1-ol-0-0-10046){ref-type="fig"}). Negative and positive controls were selected from previously diagnosed sections at the Department of Pathology, The First Affiliated Hospital of China Medical University. Positive expression of BRCA1 was associated with a significantly higher 5-year DFS rate in the FBC group (99/141, 70.2%) compared with the SBC group (21/147, 14.3%; P\<0.001). The typical staining for FANCD2 was predominantly nuclear in the benign and malignant tissues ([Fig. 1D-H](#f1-ol-0-0-10046){ref-type="fig"}). Positive expression of FANCD2 was associated with a significantly higher 5-year DFS rate in the FBC group (59/141, 41.8%) compared with the SBC group (42/147, 28.6%) (P=0.037). [Table II](#tII-ol-0-0-10046){ref-type="table"} presents the clinical characteristics of the patients and the expression levels of BRCA1 and FANCD2. Expression of BRCA1 in the FBC group was positively associated with tumor size (P=0.021), lymphatic invasion (P=0.004), TNM stage (P=0.01), ER status (P=0.014) and FANCD2 expression (P\<0.001). These associations were not observed in the SBC group. However, FANCD2 expression in SBC group was positively associated with tumor size (P=0.003), TNM stage (P\<0.001), ER status (P=0.02) and Ki-67 index (P=0.015). The benign tissues were commonly positive for BRCA1 (29/47, 61.7%) and FANCD2 (21/47, 44.7%). There was no significant association between the expression of the two proteins (P=0.587). BRCA1 and FANCD2 expression was predominantly positive in the benign tissues compared with that in the SBC tissues (BRAC1, 61.7 vs. 14.3%, P\<0.001; and FANCD2, 7 vs. 27.9%, P=0.069).

### Further analysis of BRCA1 and FANCD2 expression in breast cancer based on TCGA data

Immunohistochemistry revealed that BRCA1 and FANCD2 were expressed in BC tissues and adjacent tissues. Analysis of the GEPIA dataset demonstrated that BRCA1 and FANCD2 gene expression in BC tissues was higher than that in adjacent tissues ([Fig. 2](#f2-ol-0-0-10046){ref-type="fig"}). Furthermore, associations between FANCD2 and BRCA1 gene expression and patient clinical characteristics were assessed using TCGA dataset. The results revealed from TCGA dataset were slightly different from the results of the tissue samples analysis due to variations in the samples grouping ([Table III](#tIII-ol-0-0-10046){ref-type="table"}). BRCA1 and FANCD2 gene expression in TCGA dataset was positively associated with tumor size (both P\<0.001) and ER expression (both P\<0.001). In addition, BRCA1 and FANCD2 gene expression demonstrated a positive association. Furthermore, FANCD2 gene expression in TCGA dataset was positively associated with PR stage (P\<0.001), lymphatic invasion (P=0.017) and TNM stage (P=0.039). Results from TCGA dataset analysis were consistent with those from tissues samples analyses.

### Prognostic value of BRCA1 and FANCD2 expression

The KM curves were compared according to BRCA1 and FANCD2 status and grouping. In the FBC group, BRCA1 expression was associated with a significantly decreased DFS rate when compared with the absence of BRCA1 expression (P=0.001; [Fig. 3A](#f3-ol-0-0-10046){ref-type="fig"}). This observation was associated with a lower 5-year DFS rate (77.8 vs. 95.2%) and a shorter median DFS time (81.4 vs. 108.8 months). However, in the FBC group, there was no significant difference in prognosis whether FANCD2 expression was positive or not (P=0.328; [Fig. 3B](#f3-ol-0-0-10046){ref-type="fig"}), although the group with positive FANCD2 expression had a lower 5-year DFS rate (78 vs. 86.6%) and a shorter median DFS time (79.7 vs. 96.7 months). In the SBC group, BRCA1 expression was not associated with a significant difference in DFS rate (P=0.22; [Fig. 3C](#f3-ol-0-0-10046){ref-type="fig"}), although the group with positive BRCA1 expression had a slightly lower 5-year DFS rate (76.2 vs. 84.9%) and a shorter median DFS time (92 vs. 94.3 months). In the SBC group, FANCD2 expression was associated with significantly decreased DFS rate (P\<0.001; [Fig. 3D](#f3-ol-0-0-10046){ref-type="fig"}), with a lower 5-year DFS rate (63.4 vs. 91.5%) and a shorter median DFS time (69.7 vs. 103.3 months). These results suggested that BRCA1 and FANCD2 expression may be considered of prognostic value in patients with FBC and SBC, respectively.

### Univariable and multivariable analyses of DFS rate in patients with BC

Univariable analyses revealed that DFS rate in patients with FBC was significantly associated with TNM stage (P=0.001) and BRCA1 expression (P=0.001). DFS rate in patients with SBC was significantly associated with tumor size (P=0.001), lymphatic invasion (P=0.004), TNM stage (P\<0.001), Ki-67 index (P=0.025) and FANCD2 expression (P\<0.001). Multivariable Cox proportional hazards model demonstrated that DFS rate in patients with FBC was independently predicted by TNM stage (III--IV vs. I--II; HR, 2.042; 95% CI, 1.150--3.624; P=0.015) and BRCA1 expression (positive vs. negative; HR, 2.168; 95% CI, 1.142--4.113; P=0.018). In the SBC group, DFS rate was independently predicted by TNM stage (III--IV vs. I--II; HR, 4.361; 95% CI, 2.465--7.716; P\<0.001) and FANCD2 expression (positive vs. negative; HR, 1.192; 95% CI, 1.041--3.512; P=0.037) ([Table IV](#tIV-ol-0-0-10046){ref-type="table"}).

### FANCD2 ubiquitination is an independent prognostic factor for patients with SBC

FANCD2 ubiquitination reflects functional activation of the FA pathway ([@b7-ol-0-0-10046],[@b9-ol-0-0-10046]). Results from the present study demonstrated that FANCD2 expression was an independent prognostic factor for SBC. Western blotting of 56 randomly selected SBC tissues was performed to examine whether FANCD2 ubiquitination was associated with prognosis. Expression of FANCD2-L and FANCD2-S ([Figs. 4](#f4-ol-0-0-10046){ref-type="fig"} and [S1](#SD1-ol-0-0-10046){ref-type="supplementary-material"}) was used to calculate the L/S ratio to quantify FANCD2 ubiquitination. L/S ratios ranged from 0.13 to 1.36 (median, 0.645; [Fig. 5](#f5-ol-0-0-10046){ref-type="fig"}). The 56 cases were subsequently divided according to their L/S value into the ubiquitination^High^ (Ub^High^, ≥0.645) group and the ubiquitination^Low^ (Ub^Low^, \<0.645) group. Representative western blotting is presented in [Figs. 4](#f4-ol-0-0-10046){ref-type="fig"} and [S1](#SD1-ol-0-0-10046){ref-type="supplementary-material"}. Patients in the Ub^High^ group had significantly higher DFS than patients in the Ub^Low^ group (P=0.036; [Fig. 6](#f6-ol-0-0-10046){ref-type="fig"}). In the FBC group, patients with Ub^High^ had a significantly higher 5-year DFS rate (85.7 vs. 71.4%) and a significantly higher median DFS time (101.2 vs. 73.4 months) compared with patients with Ub^Low^. Results from the univariable and multivariable analyses are presented in [Table V](#tV-ol-0-0-10046){ref-type="table"}. Univariable analysis revealed that the DFS rate in patients with SBC was significantly associated with ubiquitination level (P=0.042). Multivariable analyses revealed that, in addition to TNM stage (P=0.003) and FANCD2 expression (P=0.006), FANCD2 ubiquitination independently predicted DFS in the SBC group (Ub^High^ vs. Ub^Low^; HR, 0.335; 95% CI, 0.128--0.875; P=0.026) ([Table V](#tV-ol-0-0-10046){ref-type="table"}).

Discussion
==========

BC is the most common malignant tumor in women in developed countries, and 10--30% of cases involve a family history, which represents a strong risk factor for BC ([@b25-ol-0-0-10046]). Based on its etiology, BC can be divided into two groups, SBC and FBC, where FBC involves a direct family history of BC. Compared with SBC, FBC affects younger women and is often associated with lymph node metastasis and negative hormone receptor expression, which leads to a poor prognosis ([@b26-ol-0-0-10046]).

Mutations of BRCA1/2 genes increase female susceptibility to BC and are closely associated with FBC. BRCA1 is involved in DNA damage repair and cell cycle regulation, and \~45% of FBC cases comprise BRCA1 mutations. Conversely, SBC is less frequently associated with gene mutations or deletions, with BRCA1/2 mutations being relatively rare in SBC ([@b27-ol-0-0-10046],[@b28-ol-0-0-10046]). The present study used immunohistochemical analysis, which cannot detect deleterious BRCA1 mutations, however, aids in understanding tumor cell physiology and confirming BRCA1 protein involvement in breast tumor cells ([@b29-ol-0-0-10046]). Previous studies reported that BRCA1 is less likely to be expressed and mutated in SBC ([@b30-ol-0-0-10046],[@b31-ol-0-0-10046]). The present study highlighted a positive association between BRCA1 expression and tumor size in the FBC group, although this result was not in accordance with previous findings ([@b31-ol-0-0-10046],[@b32-ol-0-0-10046]). This difference may be due to the inclusion in the present study of patients with first-degree relatives who had breast cancer, and/or ethnicity differences. In addition, BRCA1 expression in the FBC group was associated with lymphatic invasion and TNM stage, which was consistent with previous findings ([@b26-ol-0-0-10046],[@b27-ol-0-0-10046]). A negative association was observed between ER status and BRCA1 expression in the FBC group, as previously demonstrated by Tazzite *et al* ([@b26-ol-0-0-10046]). However, BRCA1 expression was not associated with these same factors in the SBC group. Previous studies have reported that BRCA1 expression is upregulated in BC tissues compared with that in benign breast tissues ([@b33-ol-0-0-10046],[@b34-ol-0-0-10046]), which was also demonstrated in the present study.

The present study demonstrated that larger tumor size, lymphatic invasion, higher TNM stage, negative ER expression and positive BRCA1 expression were associated with poor prognosis in patients with FBC. Scully and Livingston ([@b35-ol-0-0-10046]) reported that BRCA1 overexpression inhibits ER activation and that FBC cases are associated with negative ER expression. These findings suggest that BRCA1 may exert its tumor inhibition activity via ER. To test this hypothesis, univariable and multivariable analyses were performed in the present study, and results confirmed that BRCA1 expression was an independent prognostic factor for FBC.

Exogenous and endogenous factors, including ionizing radiation and chemical exposure, can lead to various types of DNA damage, although a DNA repair system aids in maintaining the stability and integrity of the human genome ([@b36-ol-0-0-10046]). Cross-linking is a common type of DNA damage that requires a complex repair process that mainly involves the FA pathway. Ubiquitination of FANCD2 is recognized as an important activation step in the FA pathway for DNA damage repair. Lyakhovich and Surralles ([@b37-ol-0-0-10046]) reported that inhibition of FANCD2 expression increases tumor cells sensitivity to mitomycin and γ rays, and that tumor cells with FANCD2 deletion have a significantly reduced ability to relapse. In sporadic ovarian cancer, Wysham *et al* ([@b38-ol-0-0-10046]) reported a high FANCD2 expression level in patients with early recurrence, and suggested that high FANCD2 expression is positively associated with early ovarian cancer risk. The present study revealed that FANCD2 expression was associated with tumor size, TNM stage and ER expression in the SBC group. These findings were in agreement with those from the study by van der Groep *et al* ([@b39-ol-0-0-10046]). Hölzel *et al* ([@b40-ol-0-0-10046]) similarly reported that the highest FANCD2 expression is observed in mature spermatocytes and fetal oocytes, which rapidly become proliferating germ cells. In addition, a high Ki-67 index typically reflects highly proliferative cells and rapid tumor progression ([@b41-ol-0-0-10046]). Furthermore, FANCD2 and Ki-67 co-localize in BC cells, which suggests that FANCD2 serves a role in the DNA repair of proliferating cells. Results from the present study demonstrated the positive association between FANCD2 and Ki-67 expression in the SBC group ([@b40-ol-0-0-10046]). Zhang *et al* ([@b41-ol-0-0-10046]) reported that BC tissues exhibit a significantly lower proportion of FANCD2-positive cells compared with healthy breast tissue; however, the present study did not demonstrate similar results, which may be due to the low number of benign cases included.

In the present study, high FANCD2 expression could independently predict a poor prognosis in the SBC group. These results were similar to those reported in previous studies ([@b19-ol-0-0-10046],[@b42-ol-0-0-10046]). We hypothesize that high FANCD2 expression may elevate the risk of early recurrence and distant metastasis, since it induces increased tolerability of the cancer cells to chemotherapy and radiotherapy. Radiotherapy and chemotherapy cause DNA damage that might be stabilized by upregulated DNA damage repair in tumor cells, which would result in a relatively poor prognosis ([@b39-ol-0-0-10046],[@b40-ol-0-0-10046]). Pejovic *et al* ([@b43-ol-0-0-10046]) reported that FANCD2-knockdown in mice stimulates ovarian cancer development; however, the manner in which FANCD2 affects the development of breast and ovarian cancer remains unclear.

Monoubiquitination of FANCD2 allows its translocation to the DNA repair complex through BRCA1 ([@b44-ol-0-0-10046]). FANCD2 monoubiquitination is therefore an important step that drives chromatin-associated complex assembly ([@b45-ol-0-0-10046],[@b46-ol-0-0-10046]) in response to DNA damage ([@b47-ol-0-0-10046]) during the S-phase of the normal cell cycle or during replicative stress ([@b48-ol-0-0-10046],[@b49-ol-0-0-10046]). The present study demonstrated that high FANCD2 expression was associated with a poor prognosis. The L/S ratio was used to examine the prognostic value of FANCD2 monoubiquitination status. In patients with SBC, a low L/S ratio independently predicted a poor prognosis; however, this ratio had no prognostic value in patients with FBC.

The FA/BRCA pathway involves two of the most important BC susceptibility genes, which encode BRCA1 and FANCD1/BRCA2 ([@b50-ol-0-0-10046]). BRCA1 participates in the repair process with FANCD2. In the present study, a positive association was found between FANCD2 and BRCA1 expression in patients with FBC. Kais *et al* ([@b51-ol-0-0-10046]) reported that BRCA1-deficient cells upregulate FANCD2 expression, which is crucial for cell survival and the maintenance of genomic stability, whereas FANCD2 downregulation inhibits BRCA1-deficient cells survival. Lyakhovich and Surralles ([@b37-ol-0-0-10046]) revealed that FANCD2 gene expression is strongly associated with the repopulation ability of cancer cells, and that FANCD2 depletion in these cells decreases their recurrence ability. Li *et al* ([@b52-ol-0-0-10046]) suggested that increasing the specificity of the mitoxantrone cytotoxic agent may locally target the tumors and the BRCA1/2 network to induce the cellular sensitivity of tumors with homologous recombination deficiencies. Taniguchi *et al* reported that mutations of FA-related genes (FANCA, FANCC, FANCD2, FANCE, FANCF and FANCG) without BRCA1 mutations are rare among patients with SBC and their family members ([@b53-ol-0-0-10046]). In addition, the present study demonstrated that lower FANCD2 ubiquitination level and poor prognosis of patients with SBC may be due to the suppressed conversion of FANCD2-S into FANCD2-L, which may be associated with abnormal function of the E3 ubiquitination ligase complex. Wu *et al* ([@b54-ol-0-0-10046]) reported that the product of BRCA1 expression has E3 ubiquitin ligase activity and catalyzes the ubiquitination of various substrate proteins (e.g., FANCD2, NPM and RNAPII). BRAC1 therefore aids in the regulation of cell life processes and is closely associated with tumor occurrence and development.

The main limitation to the present study was that only the association between patient clinical characteristics and BC prognosis was analyzed. The specific mechanisms of the BRCA1 and FANCD2 genes with regard to prognosis, and the reasons behind the differences in their expression in FBC and SBC were not investigated. Additional experiments using breast cancer cells and animal model are required in future investigations.

In conclusion, the present study revealed that high BRCA1 expression was associated with a poor prognosis in patients with FBC. In addition, high FANCD2 expression and low FANCD2 ubiquitination were associated with a poor prognosis in patients with SBC. These results suggested that BRCA1 and FANCD2 expression and FANCD2 ubiquitination status may be considered as crucial markers that may assist in conducting pathogenesis research and risk assessment, forming an early diagnosis and developing gene therapy. Targeting the FA/BRCA pathway may represent a novel therapeutic option, which could improve the prognosis of patients with BC.
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![Comparisons of (A) BRCA1 and (B) FANCD2 expression levels between breast cancer tissues and non-cancerous adjacent tissues. The red bar represents the tumor tissues and the gray bar indicates the non-cancerous adjacent tissues. These figures were derived from the Gene Expression Profiling Interactive Analysis dataset. \*P\<0.05. BRCA1, breast cancer type 1 susceptibility protein; FANCD2 Fanconi anemia group D2 protein.](ol-17-04-3687-g01){#f2-ol-0-0-10046}

![DFS of patients with breast cancer based on BRCA1 and FANCD2 expression. DFS of patients with FBC grouped by positive or negative expression of (A) BRCA1 and (B) FANCD2. DFS of patients with SBC were divided by positive or negative expression of (C) BRCA1 and (D) FANCD2. Probabilities of DFS were estimated using the Kaplan-Meier method and compared using the log-rank statistic. BRCA1, breast cancer type 1 susceptibility protein; FANCD2, Fanconi anemia group D2 protein; Cum, cumulative; DFS, disease-free survival; FBC, familial breast cancer; SBC, sporadic breast cancer.](ol-17-04-3687-g02){#f3-ol-0-0-10046}

![Western blot analysis of FANCD2 in patients with SBC. FANCD2 is represented by two adjacent bands. The upper stripe, L, is ubiquitinated FANCD2, and the lower stripe, S, is unubiquitinated FANCD2. Western blotting from the other 50 patients are shown in [Fig. S1](#SD1-ol-0-0-10046){ref-type="supplementary-material"}. BRCA1, breast cancer type 1 susceptibility protein; FANCD2, Fanconi anemia group D2 protein.](ol-17-04-3687-g03){#f4-ol-0-0-10046}

![Distribution of ubiquitination levels of patients with SBC. The L/S ratio of 56 patients with SBC ranged from 0.13 to 1.36, with a median ratio of 0.645. Cases were divided into FANCD2^High^ and FANCD2^Low^ groups according to the median L/S ratio of 0.645 (28 cases in each group). FANCD2, Fanconi anemia group D2 protein; SBC, sporadic breast cancer; L/S, ubiquitinated/unubiquitinated.](ol-17-04-3687-g04){#f5-ol-0-0-10046}

![DFS of patients with SBC based on the ubiquitination level of FANCD2. DFS of patients divided into FANCD2^High^ and FANCD2^Low^ groups in the SBC group. Probabilities of DFS were estimated using the Kaplan-Meier method and compared using the log-rank statistic. DFS, disease-free survival; FANCD2, Fanconi anemia group D2 protein; SBC, sporadic breast cancer.](ol-17-04-3687-g05){#f6-ol-0-0-10046}

###### 

Demographic and clinical characteristics of patients with BC in the FBS (n=141) and SBC (n=147) groups.

                                 FBC           SBC                         
  ------------------------------ ------------- ------ ------------- ------ -----
  Age in years                                                             
  Median (range)                 52 (31--76)          50 (25--79)          
    \<51, n                      69            48.9   75            51.0   144
    ≥51, n                       72            51.1   72            49.0   144
  Pathological type                                                        
    *In situ*                    21            14.9   18            12.2   39
    Invasive ductal carcinoma    81            57.4   91            61.9   172
    Invasive lobular carcinoma   25            17.7   22            15.0   47
    Others                       14            9.9    16            10.9   30
  Histological grade                                                       
    I                            43            30.5   31            21.1   74
    II                           67            47.5   78            53.1   145
    III                          31            22.0   38            25.9   69
  Tumor size                                                               
    T1                           63            44.7   72            49.0   135
    T2                           61            43.3   63            42.9   124
    T3                           16            11.3   12            8.2    28
    T4                           1             0.7    0             0.0    1
  Node involvement                                                         
    Positive                     63            44.7   56            38.1   119
    Negative                     78            55.3   91            61.9   169
  TNM stage                                                                
    I                            61            43.3   55            37.4   116
    II                           51            36.2   56            38.1   107
    III                          29            20.6   36            24.5   65
    IV                           0             0.0    0             0.0    0
  ER status                                                                
    Positive                     82            58.2   80            54.4   162
    Negative                     59            41.8   67            45.6   126
  PR status                                                                
    Positive                     67            47.5   78            53.1   145
    Negative                     74            52.5   69            46.9   143
  HER2 status                                                              
    Positive                     56            39.7   57            38.8   113
    Negative                     85            60.3   90            61.2   175
  Ki-67                                                                    
    ≥15%                         84            59.6   88            59.9   162
    \<15%                        57            40.4   59            40.1   126

BRCA1, breast cancer type 1 susceptibility protein; FANCD2, Fanconi anemia group D2 protein; ER, estrogen receptor; FBC, familial breast cancer; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor; SBC, sporadic breast cancer; TNM, Tumor-Node-Metastasis.

###### 

Expression of BRCA1 and FANCD2, and clinical characteristics of patients with BC.

                       BRCA1 in FBC group   FANCD2 in FBC group   BRCA1 in SBC group   FANCD2 in SBC group                                            
  -------------------- -------------------- --------------------- -------------------- --------------------- ---- ------- ---- ---- ------- ---- ---- ---------
  Age, years                                                                                                                                          
    \>51               49                   23                    0.567                30                    42   0.965   9    63   0.544   16   56   0.133
    ≤51                50                   19                                         29                    40           12   63           25   50   
  Histological grade                                                                                                                                  
    I--II              73                   37                    0.08                 42                    68   0.097   14   95   0.398   27   82   0.153
    III                26                   5                                          17                    14           7    31           14   24   
  Tumor size, cm                                                                                                                                      
    \>2                61                   17                    0.021                34                    44   0.64    10   65   0.736   29   46   0.003
    ≤2                 38                   25                                         25                    38           11   61           12   60   
  Lymphatic invasion                                                                                                                                  
    Positive           52                   11                    0.004                32                    31   0.053   11   45   0.145   17   39   0.601
    Negative           47                   31                                         27                    51           10   81           24   67   
  TNM stage                                                                                                                                           
    I--II              73                   39                    0.01                 44                    68   0.226   16   96   0.953   22   90   \<0.001
    III--IV            26                   3                                          15                    14           5    31           19   17   
  ER status                                                                                                                                           
    Positive           51                   31                    0.014                30                    52   0.136   10   70   0.499   16   64   0.02
    Negative           48                   11                                         29                    30           11   56           25   42   
  PR status                                                                                                                                           
    Positive           42                   25                    0.063                26                    41   0.478   13   65   0.38    22   56   0.928
    Negative           57                   17                                         33                    41           8    61           19   50   
  HER2 status                                                                                                                                         
    Positive           44                   12                    0.078                27                    29   0.213   7    50   0.58    17   40   0.677
    Negative           55                   30                                         32                    53           14   76           24   66   
  Ki-67                                                                                                                                               
    ≥15%               60                   24                    0.702                34                    50   0.689   10   78   0.216   31   57   0.015
    \<15%              39                   18                                         25                    32           11   48           10   49   
  FANCD2                                                                                                                                              
    Positive           52                   7                     \<0.001                                                 7    35   0.587             
    Negative           47                   35                                                                            14   92                     

BRCA1, breast cancer type 1 susceptibility protein; FANCD2, Fanconi anemia group D2 protein; FBC, familial breast cancer; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor; SBC, sporadic breast cancer; TNM, Tumor-Node-Metastasis.

###### 

Expression of BRCA1 and FANCD2, and clinical characteristics of patients with breast cancer obtained from The Cancer Genome Atlas dataset.

                               BRCA1   FANCD2                         
  ---------------------------- ------- -------- --------- ----- ----- ---------
  Age, years (n=1,078)                                                
    \>58                       288     275      0.428     272   291   0.241
    ≤58                        251     264                267   248   
  Tumor size, cm (n=1,077)                                            
    \>2                        389     409      \<0.001   492   306   \<0.001
    ≤2                         98      181                116   163   
  Lymphatic invasion (n=914)                                          
    Positive                   234     229      0.32      213   250   0.017
    Negative                   222     229                243   208   
  TNM stage (n=768)                                                   
    I--II                      302     292      0.32      309   285   0.039
    III--IV                    81      93                 76    100   
  ER (n=1,024)                                                        
    Positive                   390     400      \<0.001   346   445   \<0.001
    Negative                   48      187                167   68    
  PR (n=1,024)                                                        
    Positive                   340     346      0.691     302   384   \<0.001
    Negative                   173     167                211   129   
  HER2 (n=611)                                                        
    Positive                   150     134      0.158     136   148   0.739
    Negative                   154     173                161   166   
  FANCD2 (n=1,080)                                                    
    Negative                   289     253      0.031                 
    Positive                   253     288                            

BRCA1, breast cancer type 1 susceptibility protein; FANCD2, Fanconi anemia group D2 protein; ER, estrogen receptor; FBC, familial breast cancer; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor; SBC, sporadic breast cancer; TNM, Tumor-Node-Metastasis.

###### 

Univariable and multivariable analyses of disease-free survival in the two groups of patients with breast cancer.

                             FBC univariable analysis   FBC multivariable analysis                    SBC univariable analysis   SBC multivariable analysis                                                       
  -------------------- ----- -------------------------- ---------------------------- ---------------- -------------------------- ---------------------------- ----------------- ---------------- ---------------- ---------
  Age, years                                                                                                                                                                                                      
    \>51               66    0.801                      0.367                                                                    63                           0.952             0.859                             
                             (0.495--1.296)                                                                                                                   (0.557--1.628)                                      
    ≤51                75    1                                                                                                   84                           1                                                   
  Histological grade                                                                                                                                                                                              
    I--II              110   1                          0.398                                                                    109                          1                 0.227                             
    III                31    1.267                                                                                               38                           1.424                                               
                             (0.732--2.195)                                                                                                                   (0.802--2.527)                                      
  Tumor size, cm                                                                                                                                                                                                  
    \>2                78    1.480                      0.115                        1.253            0.377                      75                           2.620             0.001            1.684            0.118
                             (0.908--2.411)                                          (0.759--2.069)                                                           (1.496--4.589)                     (0.876--3.238)   
    ≤2                 63    1                                                       1                                           72                           1                                  1                
  Lymphatic invasion                                                                                                                                                                                              
    Positive           63    1.472                      0.112                        1.085            0.755                      56                           2.176             0.004            1.717            0.064
                             (0.914--2.372)                                          (0.651--1.807)                                                           (1.278--3.704)                     (0.970--3.041)   
    Negative           78    1                                                       1                                           91                           1                                  1                
  TNM stage                                                                                                                                                                                                       
    I--II              112   1                          0.001                        1                0.015                      111                          1                 \<0.001          1                \<0.001
    III--IV            29    2.461                                                   2.042                                       36                           5.925                              4.361            
                             (1.454--4.166)                                          (1.150--3.624)                                                           (3.462--10.141)                    (2.465--7.716)   
  ER status                                                                                                                                                                                                       
    Positive           82    0.634                      0.146                        0.672            0.11                       81                           0.630             0.088            0.796            0.434
                             (0.393--1.023)                                          (0.413--1.095)                                                           (0.37--1.071)                      (0.449--1.411)   
    Negative           59    1                                                       1                                           66                           1                                  1                
  PR status                                                                                                                                                                                                       
    Positive           77    0.957                      0.855                                                                    78                           0.836             0.506                             
                             (0.594--1.540)                                                                                                                   (0.493--1.418)                                      
    Negative           64    1                                                                                                   69                           1                                                   
  HER2 status                                                                                                                                                                                                     
    Positive           59    1.018                      0.943                                                                    57                           0.898             0.701                             
                             (0.626--1.655)                                                                                                                   (0.518--1.556)                                      
    Negative           82    1                                                                                                   90                           1                                                   
  Ki-67                                                                                                                                                                                                           
    ≥15%               84    1.469                      0.127                        1.384            0.204                      88                           1.907             0.025            1.194            0.569
                             (0.896--2.408)                                          (0.838--2.286)                                                           (1.086--3.350)                     (0.648--2.201)   
    \<15%              57    1                                                       1                                           59                           1                                  1                
  BRCA1                                                                                                                                                                                                           
    Positive           99    2.707                      0.001                        2.168            0.018                      21                           1.507             0.224                             
                             (1.472--4.978)                                          (1.142--4.113)                                                           (0.778--2.918)                                      
    Negative           42    1                                                       1                                           126                          1                                                   
  FANCD2                                                                                                                                                                                                          
    Positive           59    1.272                      0.334                                                                    42                           3.801             \<0.001          1.192            0.037
                             (0.781--2.073)                                                                                                                                     (2.201--6.563)   (1.041--3.512)   
    Negative           82    1                                                                                                   105                          1                                                   

BRCA1, breast cancer type 1 susceptibility protein; FANCD2, Fanconi anemia group D2 protein; CI, confidence interval; ER, estrogen receptor; FBC, familial breast cancer; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; PR, progesterone receptor; SBC, sporadic breast cancer; TNM, Tumor-Node-Metastasis.

###### 

Univariable and multivariable analyses of disease-free survival in patients with sporadic breast cancer (n=141).

                              Univariable analysis    Multivariable analysis                           
  ---------------------- ---- ----------------------- ------------------------ ----------------------- -------
  Tumor size, cm                                                                                       
    \>2                  30   2.266 (0.956--5.369)    0.063                    1.329 (0.459--3.847)    0.6
    ≤2                   26   1                                                1                       
  Lymphatic invasion                                                                                   
    Positive             27   2.545 (1.071--6.050)    0.034                    2.485 (0.896--6.895)    0.08
    Negative             29   1                                                1                       
  TNM stage                                                                                            
    I--II                39   1                       \<0.001                  1                       0.003
    III--IV              17   6.389 (2.687--15.190)                            4.236 (1.658--10.820)   
  ER status                                                                                            
    Positive             31   0.700 (0.308--1.594)    0.396                                            
    Negative             25   1                                                                        
  Ki-67 status                                                                                         
    ≥15%                 41   1.946 (0.708--5.348)    0.197                    1.705 (0.520--5.584)    0.378
    \<15%                15   1                                                1                       
  FANCD2                                                                                               
    Positive             18   3.133 (1.370--7.169)    0.007                    3.755 (1.465--9.625)    0.006
    Negative             38   1                                                1                       
  Ubiquitination level                                                                                 
    ≥0.645               28   0.403 (0.167--0.968)    0.042                    0.335 (0.128--0.875)    0.026
    \<0.645              28   1                                                1                       

FANCD2, Fanconi anemia group D2 protein; CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; TNM, Tumor-Node-Metastasis.
